HC Wainwright & Co. Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsDowngradesPrice Target
HC Wainwright & Co. analyst Andres Y. Maldonado downgrades TScan Therapeutics (NASDAQ:TCRX) from Buy to Neutral and lowers the price target from $7 to $1.
HC Wainwright & Co. analyst Andres Y. Maldonado downgrades TScan Therapeutics (NASDAQ:TCRX) from Buy to Neutral and lowers the price target from $7 to $1.